Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

Articolo
Data di Pubblicazione:
2022
Citazione:
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy / Toss, A., Venturelli, M., Civallero, M., Piombino, C., Domati, F., Ficarra, G., Combi, F., Cabitza, E., Caggia, F., Barbieri, E., Barbolini, M., Moscetti, L., Omarini, C., Piacentini, F., Tazzioli, G., Dominici, M., Cortesi, L.. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), pp. 1-11. [10.3389/fonc.2022.1016295]
Abstract:
IntroductionTriple-negative breast cancer (TNBC) patients who do not obtain pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) present higher rate of relapse and worse overall survival. Risk factors for relapse in this subset of patients are poorly characterized. This study aimed to identify the predictive factors for relapse in TNBC patients without pCR after NACT. MethodsWomen with TNBC treated with NACT from January 2008 to May 2020 at the Modena Cancer Center were included in the analysis. In patients without pCR, univariate and multivariable Cox analyses were used to determine factors predictive of relapse. ResultsWe identified 142 patients with a median follow-up of 55 months. After NACT, 62 patients obtained pCR (43.9%). Young age at diagnosis (<50 years) and high Ki-67 (20%) were signi!cantly associated with pCR. Lack of pCR after NACT resulted in worse 5-year event-free survival (EFS) and overall survival (OS). Factors independently predicting EFS in patients without pCR were the presence of multifocal disease [hazard ratio (HR), 3.77; 95% CI, 1.45-9.61; p=0.005] and residual cancer burden (RCB) III (HR, 3.04; 95% CI, 1.09-9.9; p=0.04). Neither germline BRCA status nor HER2-low expression were associated with relapse. DiscussionThese data can be used to stratify patients and potentially guide treatment decision-making, identifying appropriate candidates for treatment intensi!cation especially in neo-/adjuvant setting.
Tipologia CRIS:
Articolo su rivista
Keywords:
multifocal disease; neoadjuvant chemotherapy; pathologic response; residual cancer burden (RCB); triple-negative breast cancer
Elenco autori:
Toss, A; Venturelli, M; Civallero, M; Piombino, C; Domati, F; Ficarra, G; Combi, F; Cabitza, E; Caggia, F; Barbieri, E; Barbolini, M; Moscetti, L; Omarini, C; Piacentini, F; Tazzioli, G; Dominici, M; Cortesi, L.
Autori di Ateneo:
CAGGIA Federica
CORTESI LAURA
DOMATI Federica
DOMINICI Massimo
MOSCETTI LUCA
OMARINI Claudia
PIACENTINI Federico
Piombino Claudia
TOSS ANGELA
Link alla scheda completa:
https://iris.unimore.it/handle/11380/1305346
Link al Full Text:
https://iris.unimore.it//retrieve/handle/11380/1305346/555443/TAfonc-12-1016295.pdf
https://iris.unimore.it//retrieve/handle/11380/1305346/973965/FO2022.pdf
Pubblicato in:
FRONTIERS IN ONCOLOGY
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.2.0